MedTrace Logo

Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin

NCT00775736 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 611

Last updated 2017-01-11

No results posted yet for this study

Summary

This study is conducted in Europe. The objective of this observational study is to evaluate the number of serious side effects, when initiating NovoMix® treatment in patients with type 2 diabetes who previously used a human premix insulin under normal clinical practice

Conditions

Interventions

DRUG

biphasic insulin aspart 30

Start dose and frequency and safety data collection at the discretion of the physician following clinical practice

DRUG

biphasic insulin aspart 50

Start dose and frequency and safety data collection at the discretion of the physician following clinical practice

DRUG

biphasic insulin aspart 70

Start dose and frequency and safety data collection at the discretion of the physician following clinical practice

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Belgium
  • Luxembourg

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00775736 on ClinicalTrials.gov